CJC-1295 / Ipamorelin 6/11 Blend

CJC-1295 / Ipamorelin 6/11 Blend Combination Synergy Profile

The CJC-1295 / Ipamorelin 6/11 Blend is specifically designed to bypass single-receptor limitations, forcing a synchronized biological cascade across multiple distinct physiological pathways for exponential results.

Pharmacological Composition

Parameter	Value
Composite Ratio	Mod GRF (1-29) 6mg + Ipamorelin 11mg
Molecular Complex Output	Custom Synthesis Ratio
Synergistic Purity	>99.0% Comb.
Appearance	Lyophilized white solid

Figure 1: Cross-Pathway Receptor Action of the Blend

Dual / Tri-Phase Transduction Pattern

Detailed cascade of actions highlighting the compound synthesis:

1. Custom-engineered high-yield ratio designed for intense, heavy GH pulsatile output research.
2. Features nearly double the concentration of Ipamorelin to saturate the ghrelin receptors completely.
3. The 1:2.2 ratio ensures that no GHRH (CJC-1295) goes to waste by supplying an overwhelming amount of releasing peptide.
4. Triggers rolling, massive physiological pulses of natural GH extending over a 3-hour post-injection window.
5. Drastically heightens the systemic conversion of GH into the anabolic, tissue-building IGF-1 in the liver.

Figure 2: Multiplicative Rate of Synergistic Recovery / Output

Primary Research Results

• Synergy 1: Reserved primarily for advanced athletic recovery and body composition modulation protocols.
• Synergy 2: Heavily favors raw lipolysis (fat-burning) due to the sustained peak amplitude of the GH pulses.
• Synergy 3: Optimizes vial reconstitution parameters for heavy daily research dosing patterns.

Higher-Ratio GHRH/GHRP Formulation

The CJC-1295/Ipamorelin 6/11 Blend uses an alternative peptide ratio compared to the standard 1:1 formulation. The 6:11 ratio (6 mg CJC-1295 No DAC to 11 mg Ipamorelin per vial) reflects research suggesting that higher relative Ipamorelin doses may optimize GH pulse characteristics. The rationale is that GHRH receptor activation (via CJC-1295) serves primarily to prime somatotroph vesicles, while GHS-R1a activation (via Ipamorelin) provides the calcium-dependent exocytosis trigger. More trigger signal relative to priming may produce a sharper, more defined GH pulse.

1. The 6:11 ratio delivers approximately 1.83x more Ipamorelin per injection relative to Mod-GRF compared to the standard 1:1 blend.
2. Higher Ipamorelin concentration ensures maximal calcium mobilization in primed somatotrophs, potentially increasing the percentage of GH vesicles released per pulse.
3. The GHRH component (CJC-1295) maintains adequate somatotroph priming without exceeding the receptor saturation point.
4. The net effect may be a taller, narrower GH pulse peak (more closely mimicking physiological pulsatility) compared to equal-ratio dosing.
5. Ipamorelin’s selectivity is maintained regardless of dose ratio—no cortisol, prolactin, or appetite effects at any tested concentration.

Ratio Optimization Research

• Pulse Shape: The higher Ipamorelin ratio may produce a sharper GH spike that returns to baseline more quickly, better replicating the natural 90-minute GH pulse periodicity.
• Total GH Output: Total GH area-under-curve may be comparable between 1:1 and 6:11 ratios, but the kinetic profile differs in peak height and duration.
• Research Selection: Choose the 6:11 ratio when research objectives favor sharp GH pulses (tissue-specific anabolic signaling). Choose 1:1 for broader, sustained GH elevation.
• Same Convenience: Pre-blended single-vial format with identical reconstitution and storage protocols as the standard blend.
• Dosing: Draw based on desired per-injection microgram targets. Reconstitute with BAC water. Refrigerate. Use within 28 days.